Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial

. 2025 Jan 10 ; 43 (2) : 189-200. [epub] 20240920

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/pmid39303200

Grantová podpora
P30 CA008748 NCI NIH HHS - United States

PURPOSE: CheckMate 914 is a two-part, randomized phase III trial evaluating adjuvant nivolumab plus ipilimumab (part A) or adjuvant nivolumab monotherapy (part B) versus placebo in mutually exclusive populations of patients with localized renal cell carcinoma (RCC) at high risk of postnephrectomy recurrence. Part A showed no disease-free survival (DFS) benefit for adjuvant nivolumab plus ipilimumab versus placebo. We report results from part B. METHODS: Patients were randomly assigned (2:1:1) to nivolumab (240 mg once every 2 weeks for up to 12 doses), placebo, or nivolumab (240 mg once every 2 weeks for up to 12 doses) plus ipilimumab (1 mg/kg once every 6 weeks for up to four doses). The planned treatment duration was 24 weeks (approximately 5.5 months). The primary end point was DFS per blinded independent central review (BICR) for nivolumab versus placebo; safety was a secondary end point. RESULTS: Overall, 825 patients were randomly assigned to nivolumab (n = 411), placebo (n = 208), or nivolumab plus ipilimumab (n = 206). With a median follow-up of 27.0 months (range, 18.0-42.4), the primary end point of improved DFS per BICR with nivolumab versus placebo was not met (hazard ratio [HR], 0.87 [95% CI, 0.62 to 1.21]; P = .40); the median DFS was not reached in either arm, and 18-month DFS rates were 78.4% versus 75.4%. The HR for DFS per investigator was 0.80 (95% CI, 0.58 to 1.12; P = .19). Grade 3-4 all-cause adverse events (AEs) occurred in 17.2%, 15.0%, and 28.9% of patients with nivolumab, placebo, and nivolumab plus ipilimumab, respectively. Any-grade treatment-related AEs led to discontinuation in 9.6%, 1.0%, and 28.4%, respectively. CONCLUSION: Part B of CheckMate 914 did not meet the primary end point of improved DFS for nivolumab versus placebo in patients with localized RCC at high risk of postnephrectomy recurrence.

Zobrazit více v PubMed

National Comprehensive Cancer Network (NCCN) : Clinical Practice Guidelines in Oncology: Kidney cancer—Version 1.2024. 2023. https://www.nccn.org PubMed

Escudier B, Porta C, Schmidinger M, et al. : Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:706-720, 2019 PubMed

Haas NB, Manola J, Uzzo RG, et al. : Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-2016, 2016 PubMed PMC

Ravaud A, Motzer RJ, Pandha HS, et al. : Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375:2246-2254, 2016 PubMed

Motzer RJ, Haas NB, Donskov F, et al. : Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 35:3916-3923, 2017 PubMed PMC

Motzer RJ, Ravaud A, Patard JJ, et al. : Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: Subgroup analyses and updated overall survival results. Eur Urol 73:62-68, 2018 PubMed PMC

Powles T, Albiges L, Bex A, et al. : ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol 32:1511-1519, 2021 PubMed

Kjaer M, Iversen P, Hvidt V, et al. : A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 21:285-289, 1987 PubMed

Messing EM, Manola J, Wilding G, et al. : Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21:1214-1222, 2003 PubMed

Aitchison M, Bray CA, Van Poppel H, et al. : Adjuvant 5-fluorouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: Results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial. Eur J Cancer 50:70-77, 2014 PubMed

Passalacqua R, Caminiti C, Buti S, et al. : Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): A phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). J Immunother 37:440-447, 2014 PubMed

Jocham D, Richter A, Hoffmann L, et al. : Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 363:594-599, 2004 PubMed

Wood C, Srivastava P, Bukowski R, et al. : An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial. Lancet 372:145-154, 2008 PubMed

Choueiri TK, Tomczak P, Park SH, et al. : Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 385:683-694, 2021 PubMed

Powles T, Tomczak P, Park SH, et al. : Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23:1133-1144, 2022 PubMed

Choueiri TK, Tomczak P, Park SH, et al. : Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med 390:1359-1371, 2024 PubMed

Pal SK, Uzzo R, Karam JA, et al. : Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): A multicentre, randomised, double-blind, phase 3 trial. Lancet 400:1103-1116, 2022 PubMed

Allaf M, Kim SE, Harshman LC, et al. : LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Ann Oncol 33:S1432-S1433, 2022. (suppl 7)

Motzer RJ, Tannir NM, McDermott DF, et al. : Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277-1290, 2018 PubMed PMC

Motzer RJ, McDermott DF, Escudier B, et al. : Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 128:2085-2097, 2022 PubMed PMC

Weber J, Mandala M, Del Vecchio M, et al. : Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377:1824-1835, 2017 PubMed

Kelly RJ, Ajani JA, Kuzdzal J, et al. : Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 384:1191-1203, 2021 PubMed

Bajorin DF, Witjes JA, Gschwend JE, et al. : Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384:2102-2114, 2021 PubMed PMC

Motzer RJ, Russo P, Grünwald V, et al. : Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomised, phase 3 trial. Lancet 401:821-832, 2023 PubMed PMC

Motzer RJ, Russo P, Grünwald V, et al. : Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial. J Clin Oncol 41, 2023. (suppl 16; abstr 4506)

Motzer RJ, Escudier B, McDermott DF, et al. : Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803-1813, 2015 PubMed PMC

Motzer RJ, Escudier B, George S, et al. : Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer 126:4156-4167, 2020 PubMed PMC

Ahmed N, Vengalasetti Y, Haslam A, et al. : Association of adjuvant or metastatic setting with discontinuation of cancer drugs in clinical trials. JAMA Netw Open 5:e2212327, 2022 PubMed PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03138512

Najít záznam

Citační ukazatele

Možnosti archivace